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Background
Myocardial fibrosis as detected by late gadolinium
enhanced cardiovascular MR (LGE-CMR) is common in
patients with hypertrophic cardiomyopathy (HCM)
although its clinical significance is uncertain. Current
standard 2D LGE CMR imaging However, a recent post-
mortem report demonstrated an isolated foci of papillary
muscle scarring which was not detected by conventional
2D LGE-CMR imaging. Three-dimensional high resolu-
tion (3D-HR) LGE CMR imaging has the potential for
minimizing the partial volume (blood/papillary scar)
effect of lower resolution/conventional 2D imaging and
may improve our sensitivity for detecting myocardial
fibrosis. Therefore, we sought to determine if 3D-HR LGE-
CMR has a diagnostic advantage over conventional 2D
LGE CMR for the detection of myocardial fibrosis in HCM
patients.
Methods
Our study compared standard two-dimensional LGE
imaging with high resolution, three-dimensional LGE
imaging for the detection of myocardial fibrosis in a
cohort of patients with hypertrophic cardiomyopathy.
Conventional 2D LGE-CMR were acquired 15–20 min-
utes post injection of 0.2 mmol/kg GdDTPA, using an
ECG-triggered, 40 views per RR, 1 RR between inversions,
TI adjusted to null myocardium, fat saturation, 2 × 2 × 8
(skip 2) mm true spatial resolution, 10–12 short-axis
slices, TR/TE/θ = 4.1 ms/1.7 ms/20° sequence. The 3D
LGE-CMR acquisition immediately followed the 2D
acquisition. Imaging parameters were the same except:
respiratory motion compensation with navigator-gating,
TR/TE/θ = 5.7 ms/2.8 ms/25°, 26 views per RR, with 1.4 ×
1.4 × 5 mm true spatial resolution. 2D and 3D LGE-CMR
images were obtained in 13 HCM subjects (35 ± 21 years;
38% male). All regions of LGE in the left ventricle (LV)
and papillary muscles were assessed visually, by 2 inde-
pendent readers (CJH and EA).
Results
Seven (54%) of 13 HCM subjects (mean LVEF 72%, range
58–82%; maximal LV wall thickness 20 mm, range 12–50
mm) had LV myocardial wall LGE on both 2D and 3D-HR
images. On the 3D-HR images, 2/13 (15%) subjects had
papillary muscle enhancement, whereas on the 2D
images, 0/13 subjects had papillary muscle enhancement.
Agreement between readers for presence/absence of papil-
lary muscle LGE was 100%.
Conclusion
These data suggest that 3D-HR LGE CMR imaging can
detect myocardial fibrosis not visualized by traditional 2D
LGE CMR imaging. Further studies are needed to assess
whether high resolution scar imaging should be incorpo-
rated into the routine assessment of scar in all HCM
patients undergoing CMR examination.
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